Hepatitis C therapy: highlights from the 2012 annual meeting of the European Association for the Study of the Liver.

Abstract	The results from clinical trials testing new direct-acting antivirals (DAAs) for chronic hepatitis C were the major focus of interest at the 2012 annual meeting of the European Association for the Study of the Liver. Besides triple combinations, in which any one of the new DAAs is given along with peginterferon-α/ribavirin, clinical trials exploring interferon-free oral regimens combining several DAAs attracted major attention. The good tolerance, broad hepatitis C virus (HCV) genotype activity, and high resistance barrier of sofosbuvir make this nucleotide analogue one of the most promising DAAs. Among HCV protease inhibitors, the safety, potency, and convenient dosing of simeprevir, asunaprevir, faldaprevir, and ABT-450/r were particularly highlighted. Among NS5A inhibitors, the good performance of daclatasvir encourages further clinical development. Finally, intriguing results were released about the role of interleukin 28B (IL-28B) polymorphisms using interferon-free regimens, indirectly supporting the role of innate immunity for clearing HCV definitively.
Authors	Pablo Barreiro, Eugenia Vispo, Eva Poveda, Jose V Fernández-Montero, Vincent Soriano
Journal	Clinical infectious diseases : an official publication of the Infectious Diseases Society of America (Clin Infect Dis) Vol. 56 Issue 4 Pg. 560-6 (Feb 2013) ISSN: 1537-6591 [Electronic] United States
PMID	23090932 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Antiviral Agents Carbamates IFNL3 protein, human Imidazoles Interleukins Protease Inhibitors Pyrrolidines Viral Nonstructural Proteins Interferons Uridine Monophosphate NS-5 protein, hepatitis C virus Valine daclatasvir Sofosbuvir
Topics	Antiviral Agents (therapeutic use) Carbamates Clinical Trials as Topic Congresses as Topic Drug Therapy, Combination Hepacivirus (drug effects) Hepatitis C, Chronic (drug therapy) Humans Imidazoles (therapeutic use) Interferons Interleukins (therapeutic use) Protease Inhibitors (therapeutic use) Pyrrolidines Sofosbuvir Uridine Monophosphate (analogs & derivatives, therapeutic use) Valine (analogs & derivatives) Viral Load Viral Nonstructural Proteins (antagonists & inhibitors, therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!